Lundbæk K.Diabetic angiopathy, a specific vascular disease. Lancet1954; 1: 377-9.
2.
Mogensen CEMicroalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas. In Mogensen CE (ed.) The Kidney and Hypertension in Diabetes Mellitus, 5th ed. Boston, Dordrecht , London. Kluwer Academic Publishers , 2000: 655-706.
3.
Mogensen CECombined high blood pressure and glucose in type 2 diabetes: Double Jeopardy . BMJ1998; 317:693-4.
4.
The Heart Outcomes Prevention Evaluation Study Investigators.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients. New Engl J Med2000; 342:145-53.
5.
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet2000; 355: 253-9.
6.
The Diabetes Control and Complications Trial Research Group.Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med2000; 342: 381-9.
7.
UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ1998; 317:703-13.
8.
Hansson L., Zanchetti A., Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet1998 ; 13:1755-62.
9.
Gæde P., Vedel P., Parving H-H., Pedersen O.Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet1999; 353:617-22.
10.
Guidelines subcommittee.1999World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. J Hypertens1999; 17:151-83.
11.
Hansson L., Lindholm LH, Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril Prevention Project (CAPPP) randomised trial. Lancet1999; 353: 611-16.
12.
Estacio RO, Jeffers BW, Hiatt WR et al.The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension . N Engl J Med1998; 338:645-53.
13.
Toumilehto J., Rastenyte D., Birkenhäger W. et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med1999; 340; 677-84.
14.
Hansson L., Lindholm LH, Ekbom T. et al. for the STOP-Hypertension-2 study Group.Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999; 354:1751-6.
15.
Mogensen CE , Neldam S.,Tikkannen I. et al. for the CALM Study Group.Randomised controlled trial of dual blockade of the renin-angiotensin system in hypertensive, microalbuminuric, non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ2000. (Submitted for publication)
16.
Mogensen CE , Christensen CKPredicting diabetic nephropathy in insulin-dependent patients. N Engl J Med1984; 311:89-93.
17.
Mogensen CE , sterby R., Hansen KW, Damsgaard EMBlood pressure elevation versus abnormal albuminuria in the genesis and prediction of renal disease in diabetes. Diabetes Care1992; 15: 1192-204.
18.
Mogensen CE , Keane WF, Bennett PH et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet1995; 346:1080-4.
19.
Mogensen CE , Vestbo E., Poulsen PL et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion . Diabetes Care1995; 18: 572-81.
20.
Viberti GC, Mogensen CE, Groop L., Pauls JF for the European Microalbuminuria Captopril Study Group.Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria . JAMA1994; 271: 275-9.
21.
Laffel LMB , McGill JB, Gans DJ on behalf of the North American Microalbuminuria Study Group.The beneficial effect of angiotensin-converting-enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. AmJMed1995; 99:497-504.
22.
The Euclid Study Group.Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet1997; 349:1787-92.
23.
Bojestig M. , Karlberg B., Verho M and the Prima Study Group.ACE inhibition during two years did not improve urinary excretion in normotensive microalbuminuric patients. Diabetologia1998; 41:A544.
24.
Crepaldi G. , Carta Q., Deferrari G. et al. for the Italian Microalbuminuria Study Group in IDDM. Diabetes Care1998; 21:104-10.
25.
Mathiesen ER , Hommel E., Hansen HP, Smidt UM, Parving H-H.Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria . BMJ1999; 319; 24-5.
26.
Jerums G on behalf of the Melbourne Diabetic Nephropathy Study Group, Melbourne, Australia.ACE inhibition vs. calcium-channel blockade in normotensive type 1 and type 2 diabetic patients with microalbuminuria. Nephrology Dial Trans1998; 13:1065-66.
27.
Ebbehøj E., Poulsen PL, Nosadini R., Fioretto R., Fioretto P., Crepaldi C., Mogensen CEEarly ACE-I intervention in microalbuminuria: 24h BP, renal function and exercise changes. Abstract of the 34th Annual Meeting of the EASD Barcelona, Spain 8-12 Sept. 1998. Diabetologia1998; 41(1).
28.
Rudberg S., sterby R., Bangstad H-J., Dahlquiest G., Persson B.Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia1999; 42: 589-95.
29.
Hovind P., Rossing P., Tarkow L., Smidt UM, Parving H-H.Progression of diabetic nephropathy. Kidney International (In press).
30.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RDThe effect of angiotensin converting enzyme inhibition on diabetic nephropathy . N Engl J Med1993; 118: 577-81.
31.
Mogensen CE , Mau Pedersen M., Ebbehøj E. et al. Combination therapy in hypertension-associated diabetic renal disease. Int J Clin Pract suppl.1997: 52-8.
Stratton IM , Adler AI, Neil AW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ2000; 321: 405-12.
34.
Adler AI, Stratton IM, Neil AW et al.Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study . BMJ2000; 321: 412-9.
